循環器内科 Twitter アカウントlanguage English

英文総説 "2010～2019" Review Papers in English


＞2019　＞2018　＞2017　＞2016　＞2015
＞2014　＞2013　＞2012　＞2011　＞2010

緑色のタイトル部分をクリックすると、総説PDFが表示されます。

【 2019 年 】（IF: 2018 年）

  1. Shimokawa H, Godo S. Nitric oxide and endothelium-dependent hyperpolarization mediated by hydrogen peroxide in health and disease. Basic Clin Pharmacol Toxicol. doi: 10.1111/bcpt.13377. [Epub ahead of print] (IF=2.452)

  2. Shimokawa H, Nagao T, Komori K. Tribute to Paul M. Vanhoutte, MD, PhD (1940-2019) Circ J. 83:2391-2393,2019. DOI:https://doi.org/10.1253/circj.CJ-19-0909 (IF=3.025)

  3. Boulanger CM, Baretella O, Blaise G, Bond RA, Cai Y, Calvin KY CK, Chataigneau T, Chen MJ, Chen H, Cheng Y, Clement DL, Cohen RA, Collis M, Danser AHJ, de Mey J, Detremmerie CMS, Duprez D, Feletou M, Flavahan N, Gao Y, Guo Y, Houston DS, Huang IB, Huang Y, Iliano S, Junquero D, Katusic ZS, Komori K, Lee MYK, Leung SWS, Li Z, Liang SC, Liu JTC, Luscher TF, Michel F, Miller VM, Mombouli JV, Morrison K, Sheila SM, O’Rourke S, Perrault L, Quignard JF, Rusch NJ, Sanchez-Ferrer CF, Schini-Kerth V, Shen K, Shi Y, Song E, Sun KWY, Taddei S, Tang EHC, Tuncer M, van den Ende R, Vedernikov Y, Verbeuren TJ, Webb C, Weigert A, Wong KHK, Xu C, Yang K, Ying F, Zellers T, Zhao Y, Zou Q, Shimokawa H.
    Tribute to Paul M. Vanhoutte, MD PhD (1940-2019). Arterioscler Thromb Vasc Biol. 39:2445-2447,2019. (IF=6.618)

  4. Satoh K, Kikuchi N, Kurosawa R, Shimokawa H. Checkpoint kinase 1 promotes the development of pulmonary arterial hypertension. (Editorial) Arterioscler Thromb Vasc Biol. 39:1504-1506,2019. (IF=6.618)

  5. Satoh J, Yokono K, Ando R, Asakura T, Hanzawa K, Ishigaki Y, Kadowaki T, Kasuga M, Katagiri H, Kato Y, Kurosawa K, Miura M, Nakamura J, Nishitsuka K, Ogawa S, Okamoto T, Sakuma S, Sakurai S, Satoh H, Shimauchi H, Shimokawa H, Shoji W, Sugiyama T, Suwabe A, Tachi M, Takahashi K, Takahashi S, Terayama Y, Tomita H, Tsuchiya Y, Waki H, Watanabe T, Yahata K, Yamashita H. Diabetes care providers' manual for disaster diabetes care. J Diabetes Investig. 10:1118-1142,2019. (IF=3.902)

  6. Satoh K, Satoh T, Yaoita N, Shimokawa H. Recent advances in the understanding of thrombosis. (Review) Arterioscler Thromb Vasc Biol. 39:e159-e165,2019. (IF=6.618)

  7. Satoh J, Yokono K, Ando R, Asakura T, Hanzawa K, Ishigaki Y, Kadowaki T, Kasuga M, Katagiri H, Kato Y, Kurosawa K, Miura M, Nakamura J, Nishitsuka K, Ogawa S, Okamoto T, Sakuma S, Sakurai S, Satoh H, Shimauchi H, Shimokawa H, Shoji W, Sugiyama T, Suwabe A, Tachi M, Takahashi K, Takahashi S, Terayama Y, Tomita H, Tsuchiya Y, Waki H, Watanabe T, Yahata K, Yamashita H. Diabetes care providers' manual for disaster diabetes care. Diabetol Int. 2019 Jun 14;10(3):153-179. doi: 10.1007/s13340-019-00397-7. eCollection 2019 Jul.

  8. Nagai M, Forster CY, Dote K, Shimokawa H. Sex hormones in heart failure revisited? (Editorial). Eur J Heart Fail. 21:308-310,2019. DOI: https://doi.org/10.1002/ejhf.1408 (IF=13.965)

  9. Ohyama K, Matsumoto M, Shimokawa H. Coronary artery spasm and perivascular adipose tissue inflammation: Insights from translational imaging research. Eur Cardiol Review. 2019;14(1):6-9. DOI: https://doi.org/10.15420/ecr.2019.3.2

  10. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, Kitakaze M, Kinugawa K, Kihara Y, Goto Y, Komuro I, Saiki Y, Saito Y, Sakata Y, Sato N, Sawa Y, Shiose A, Shimizu W, Shimokawa H, Seino Y, Node K, Higo T, Hirayama A, Makaya M, Masuyama T, Murohara T, Momomura SI, Yano M, Yamazaki K, Yamamoto K, Yoshikawa T, Yoshimura M, Akiyama M, Anzai T, Ishihara S, Inomata T, Imamura T, Iwasaki YK, Ohtani T, Onishi K, Kasai T, Kato M, Kawai M, Kinugasa Y, Kinugawa S, Kuratani T, Kobayashi S, Sakata Y, Tanaka A, Toda K, Noda T, Nochioka K, Hatano M, Hidaka T, Fujino T, Makita S, Yamaguchi O, Ikeda U, Kimura T, Kohsaka S, Kosuge M, Yamagishi M, Yamashina A; Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group. JCS 2017/JHFS 2017 Guideline on diagnosis and treatment of acute and chronic heart failure -Digest version. Circ J. 83:2084-2184,2019. (IF=3.025)

  11. Kikuchi N, Satoh K, Saito Y, Shimokawa H. Selenoprotein P promotes the development of pulmonary arterial hypertension: A possible novel therapeutic target. (Authors’ reply) Circulation. 139:724-725,2019. (IF=23.054)

  12. Crea F, Merz CNB, Beltrame JF, Berry C, Camici PG, Kaski JC, Ong P, Pepine CJ, Sechtem U, Shimokawa H. Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. Eur Heart J. 40:2455-2462,2019. (IF=24.889)

  13. Satoh K, Shimokawa H. Sirtuin 5 promotes ischemia/reperfusion-induced blood-brain barrier damage after stroke. (Editorial) Int J Cardiol. 284:77-78,2019. (IF=3.471)

  14. Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, Sakamoto T, Tsujita K, Hagiwara N, Miyazaki S, Ako J, Arai H, Ishii H, Origuchi H, Shimizu W, Takemura H, Tahara Y, Morino Y, Iino K, Itoh T, Iwanaga Y, Uchida K, Endo H, Kongoji K, Sakamoto K, Shiomi H, Shimohama T, Suzuki A, Takahashi J, Takeuchi I, Tanaka A, Tamura T, Nakashima T, Noguchi T, Fukamachi D, Mizuno T, Yamaguchi J, Yodogawa K, Kosuge M, Kohsaka S, Yoshino H, Yasuda S, Shimokawa H, Hirayama A, Akasaka T, Haze K, Ogawa H, Tsutsui H, Yamazaki T; Japanese Circulation Society Joint Working Group. JCS 2018 Guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 83:1085-1196,2019. (IF=3.025)

  15. Fukuda K, Date H, Doi S, Fukumoto Y, Fukushima N, Hatano M, Ito H, Kuwana M, Matsubara H, Momomura SI, Nishimura M, Ogino H, Satoh T, Shimokawa H, Yamauchi-Takihara K, Tatsumi K, Ishibashi-Ueda H, Yamada N, Yoshida S, Abe K, Ogawa A, Ogo T, Kasai T, Kataoka M, Kawakami T, Kogaki S, Nakamura M, Nakayama T, Nishizaki M, Sugimura K, Tanabe N, Tsujino I, Yao A, Akasaka T, Ando M, Kimura T, Kuriyama T, Nakanishi N, Nakanishi T, Tsutsui H; Japanese Circulation Society and the Japanese Pulmonary Circulation and Pulmonary Hypertension Society Joint Working Group. Guidelines for the treatment of pulmonary hypertension (JCS 2017/JPCPHS 2017). Circ J. 83:842-945,2019. (IF=3.025)

【 2018 年 】（IF: 2017 年）

  1. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Ruschitzka F, Lüscher TF, Templin C. International expert consensus document on Takotsubo syndrome (Part I): Clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J. 39:2032-2046,2018. (IF=23.425)

  2. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Ruschitzka F, Lüscher TF, Templin C. International expert consensus document on Takotsubo syndrome (Part II): Diagnostic workup, outcome, and management. Eur Heart J. 39:2047-2062,2018. (IF=23.425)

  3. Nochioka K, Sakata Y, Shimokawa H. Combination therapy of renin angiotensin system inhibitors and β-blockers in patients with heart failure. Adv Exp Med Biol. 1067:17-30,2018. (IF=1.760)

  4. Ohyama K, Matsumoto Y, Takahashi J, Takanami K, Shimokawa H. New aspects of vasospastic angina: coronary adventitial and perivascular adipose tissue inflammation. (Authors’ reply) J Am Coll Cardiol. 2018;71:2709-10. (IF=16.834)

  5. Ong P, Camici PG, Beltrame JF, Crea F, Shimokawa H, Sechtem U, Kaski JC, Noel Bairey Merz C; Coronary Vasomotion Disorders International Study Group (COVADIS). The microvascular network connecting extracardiac arteries to the heart. (Authors’ reply) Int J Cardiol. 259:56,2018. (IF=4.034)

  6. Sakata Y, Tsuji K, Nochioka K, Shimokawa H. Transition of left ventricular ejection fraction in heart failure. Adv Exp Med Biol.1067:5-15,2018. (IF=1.760)

  7. Satoh K, Kikuchi N, Satoh T, Kurosawa R, Sunamura S, Siddique MAH, Omura J, Yaoita N, Shimokawa H. Identification of novel therapeutic targets for pulmonary arterial hypertension. Int. J. Mol. Sci. 2018,19(12), 4081; DOI: https://doi.org/10.3390/ijms19124081 (IF=3.687)

  8. Satoh K, Shimokawa H. Recent advances in the development of cardiovascular biomarkers. Arterioscler Thrmb Vasc Biol. 38:e61-e70,2018. (IF=6.086)

  9. Yaoita N, Shimokawa H. The effect of heart rate reduction in pulmonary arterial hypertension, (Editorial) Am J Physiol. 314:H889-H891,2018. (IF=3.077)

【 2017 年 】（IF: 2016 年）

  1. Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 219(1):22-96,2017. (IF=4.867)

  2. Aoki T, Shimokawa H. Earthquake and hypertension-from acute to chronic phase after the Great East Japan Earthquake. J Xiangya Med. 2:9,2017.

  3. Beltrame J, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, Shimokawa H, Merz CNB; COVADIS Group. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 38:2565-2568,2017. (IF=20.212)/li>
  4. Crea F, Merz CNB, Beltrame JF, Kaski JC, Ogawa H, Ong P, Sechtem U, Shimokawa H, Camici P: COVADIS Group. The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. Eur Heart J. 38:473-477,2017. (IF=20.212)

  5. Godo S, Shimokawa H. Recent highlights of ATVB: Endothelial functions. Arterioscler Thromb Vasc Biol. 37:e108-e114,2017. (IF=6.607)

  6. Godo S, Shimokawa H. Divergent roles of endothelial nitric oxide synthases system in maintaining cardiovascular homeostasis. Free Radical Biology & Medicine. 109:4-10,2017. (IF=5.606)

  7. Nishimiya K, Matsumoto Y, Shimokawa H. Viewpoint: Recent advances in intracoronary imaging for vasa vasorum visualisation. Eur Cardiol Rev. 2017;12 (2):ePub: 20 November 2017.

  8. Ohyama K, Matsumoto Y, Shimokawa H. Impact of epicardial adipose tissue volume quantified by non-contrast electrocardiogram-gated computed tomography on ergonovine-induced epicardial coronary artery spasm. (Letter to the Editor) Int J Cardiol. 229:40,2017. (IF=6.189)

  9. Satoh K, Takahashi J, Matsumoto Y, Tatebe S, Aoki T, Kikuchi Y, Hao K, Ohyama K, Nogi M, Suda A, Kasahara S, Sato K, Ichijo S, Shimokawa H. European Society of Cardiology (ESC) Annual Congress Report From Barcelona 2017. Circ J. 81:1758-1763,2017. (IF=3.544)

  10. Shimokawa H, Kikuchi N, Satoh K. Shrinking basic cardiovascular research in Japan -The tip of the iceberg- Circ Res. 121:331-334,2017. (IF=13.965) (プレスリリース、8月31日)

  11. Ventura-Clapier R, Dworatzek E, Seeland U, Kararigas G, Arnal JF Brunelleschi S, Carpenter T, Erdmann J, Franconi F, Giannetta E, Glezerman M, Hofmann S, Junien C, Katai M, Kublickiene K, Konig IR, Majdic G, Malorni W, Mieth C, Miller V, Reynolds R, Shimokawa H, Tannenbaum C, D`Ursi AM, Regitz-Zagrosek V. Sex in basic research -Concepts in the cardiovascular field- Cardiovasc Res. 113:711-724,2017. (IF=5.878)

【 2016 年 】

  1. Beltrame JF, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, Shimokawa H, Merz CNB, the COVADIS Group. The who, what, why, when, how and where of vasospastic angina. Circ J. 80:289-298,2016.

  2. JCS, JSH and JCC Joint Working Group (Shimokawa H, Kario K, Daida H, et al.) Guidelines for disaster medicine for patients with cardiovascular disease (JCS 2014/JSH 2014/JCC 2014). Circ J. 80:261-284,2016.

  3. Konishi M, Ishida J, Springer J, von Haehling S, Akashi YJ, Shimokawa H, Anker SD. Heart failure epidemiology and novel treatments in Japan: facts and numbers. (Editorial) ESC Heart Failure. 3:145-151,2016.

  4. Merz CN, Beltrame J, Camici P, Crea F, Kaski JC, Ogawa H, Peter P, Sechtem U, Shimokawa H. A shocking development in a young male athlete with chest pain (Letter to the Editor). Circulation. 133:756-763,2016.

  5. Shimokawa H. The 8-year journey with the Circulation Journal. (Editorial) Circ J. 80:1661-1664,2016.

  6. Shimokawa H, Godo S. Diverse functions of endothelial NO synthases system: NO and EDH. J Cardiovasc Pharmacol. 67:361-366，2016.

  7. Shimokawa H, Sunamura S, Satoh K. RhoA/Rho-kinase in the cardiovascular system. Circ Res. 118:352-366,2016.

  8. Sugimura K, Satake H, Shimokawa H. Respiratory therapy in chronic heart failure patients complicated with sleep-disordered breathing: potential study bias. (Author's reply) Circ J. 80:1486-1487,2016.

  9. Sugimura K, Shimokawa H. Ischemic lesion formation in solitary tract nuclei during central sleep apnea with heart failure -Authors’ reply- Circ J. 80:1049,2016.

  10. Takahashi J, Satoh K, Fukuda K, Sugimura K, Matsumoto Y, Nakano M, Tsuburaya R, Aoki T, Hao K, Nishimiya K, Ito K, Sakata Y, Shimokawa H. Overview of the 80th annual scientific meeting of the Japaanese Circulation Society. -The Past, Present and Future Cardiovascular Medicine in Japan- -The 5th anniversary of the Great East Japan Earthquake- Circ J. 80:1689-1694,2016.

  11. Yaoita N, Satoh K, Shimokawa H. Novel therapeutic targets of pulmonary hypertension. (Review) Arteriosclr Thromb Vasc Biol. 2016;36:e97-e102. DOI: 10.1161/ATVBAHA.116.308263.

【 2015 年 】

  1. Ito K, Shimokawa H. The future of non-invasive angiogenic therapy using acoustic waves. Circ J. 79:1906-1907,2015.

  2. Shimokawa H, Miura M, Nochioka K, Sakata Y. Heart failure as a general pandemic in Asia. Eur J Heart Fail. 17:884-892,2015

  3. Shimokawa H, Satoh K. 2015 ATVB Plenary lecture: Translational research on Rho-kinase in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 35:1756-1769,2015.

  4. Shimokawa H, Satoh K. Light and dark of reactive oxygen species for vascular function. J Cardiovasc Pharmacol. 65:412-418,2015.

  5. Satoh K, Kikuchi N, Kurosawa R, Shimokawa H. PDE1C negatively regulates growth factor receptor degradation and promotes VSMC proliferation. Circ Res. 116:1098-1100,2015.

  6. Satoh K. Cyclophilin A in cardiovascular homeostasis and diseases. Tohoku J Exp Med. 235:1-15,2015.

  7. Tsutsui M, Tanimoto A, Tamura M, Mukae H, Yanagihara N, Shimokawa H, Otsuji Y. Significance of nitric oxide synthases: Lessons from triple nitric oxide synthases null mice. J Pharmacol Sci. 127:42-52,2015.

【 2014 年 】

  1. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Siswanto BB, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 1:4-25,2014.

  2. Satoh K, Godo S, Saito H, Enkhjargal S, Shimokawa H. Dual roles of vascular-derived reactive oxygen species -With a special reference to hydrogen peroxide and cyclophilin A- J Mol Cell Cardiol. 73:50-56,2014.

  3. Satoh K, Shimokawa H. High-sensitivity C-reactive protein: Still need for next-generation biomarkers for remote future cardiovascular events. Eur Heart J. 35:1776-1778,2014. (Editorial)

  4. Shimokawa H. 2014 William Harvey Lecture. Importance of coronary vasomotion abnormalities -From bench to bedside- Eur Heart J. 35:3180-3193,2014.

  5. Shimokawa H, Ogawa H. Prognostic stratefication of patients with vasospastic angina. J Am Coll Cardiol. 63:1585-1586,2014.

  6. Shimokawa H, Satoh K. Recent Highlights of ATVB: Vascular function. Arteriosclr Thromb Vasc Biol. 34:2359-2362,2014.

  7. Suzuki H, Matsumoto Y, Shimokawa H. Cerebral blood flow in Takotsubo syndrome: Is it specific for the disease? -Reply- Circ J. 78:776,2014.

  8. Tsutsui M, Shimokawa H, Tanimoto A, Yanagihara N, Otsuji Y. Roles of nitric oxide synthases in arteriosclerotic vascular disease-Insights from murine genetic models- J Clin Exp Cardiol. 5: 318. doi:10.4172/2155-9880.1000318,2014.

【 2013 年 】

  1. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J. 77:2209-2217,2013.

  2. Sakata Y, Shimokawa H. Saturated fatty acid intake and cardiovascular risk. Eur Heart J. 34:1178-1180,2013.

  3. Shibata K, Shimokawa H, Yanagisawa N, Otsuji Y, Tsutsui M. Nitric oxide synthases and heart failure -Lessons from genetically manipulated mice- J UOEH. 35:147-158,2013.

  4. Shimokawa H. Reactive oxygen species promote vascular smooth muscle cell proliferation. Circ Res. 113:1040-1042,2013.

【 2012 年 】

  1. Kagaya Y, Asaumi Y, Wang W, Takeda M, Nakano M, Satoh K, Fukumoto Y, Shimokawa H. Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target. Tohoku J Exp Med. 227:83-91,2012.

  2. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? Eur Heart J. 33:436-443,2012.

  3. Satoh K, Fukumoto Y, Nakano M, Kagaya Y, Shimokawa H. Emergence of the erythropoietin/erythropoietin receptor system as a novel cardiovascular therapeutic target. J Cardiovasc Pharmacol. 58:570-574,2012.

  4. Shiba N, Shimokawa H. Prospective care of heart failure in Japan: Lessons from CHART Studies. EPMA. 2:425-438,2012.

【 2011 年 】

  1. Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J. 75:1801-1810,2011.

  2. Ito K, Fukumoto Y, Shimokawa H. Extracorporeal shock wave therapy for ischemic cardiovascular disorders. Am J Cardiovasc Drugs. 11:295-302,2011.

  3. Satoh K, Berk BC, Shimokawa H. Vascular-derived reactive oxygen species for homeostasis and diseases. Nitric Oxide. 25:211-215,2011.

  4. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: Important new therapeutic target in cardiovascular diseases. Am J Physiol. 301:287-296,2011.

  5. Shiba N, Shimokawa H. Chronic kidney disease and heart failure--Bidirectional close link and common therapeutic goal. J Cardiol. 57:8-17,2011.

【 2010 年 】

  1. Ito K, Kagaya Y, Shimokawa H. Thyroid hormone and chronically unloaded hearts. Vasc Pharmacol. 52:138-141,2010.

  2. Shimokawa H. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pflugers Arch Eur J Physiol. 459:915-922,2010.

  3. Shimokawa H, Tustsui M. Nitric oxide synthases in the pathogenesis of cardiovascular disease. Pflugers Arch Eur J Physiol. 459:959-967,2010.

  4. Tsutsui M, Shimokawa H, Otsuji Y, Yanagihara N. Pathophysiological relevance of NO signaling in the cardiovascular system: novel insight from mice lacking all NO synthases. Pharmacology & Therapeutics. 128:499-508,2010.